Radiosynthesis of 18F-(R8,15,21, L17)-vasoactive intestinal peptide and preliminary evaluation in mice bearing C26 colorectal tumours.

Cheng D, Yin D, Zhang L, Wang M, Li G, Wang Y

Nuclear medicine communications1 Jun 2007Cited by 2 (Europe PMC)

PMID17460542DOI10.1097/mnm.0b013e328155d111PepBankPUB-17460542

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

2 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Pharmacokinetics
In mice bearing C26 colorectal tumours, the 18F-labelled VIP analogue cleared rapidly from the blood.
In plain wordsIn mice with colorectal tumours, the labelled VIP analogue left the blood quickly.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableBlood clearance of the labelled VIP analogue
Study
mousen: not reported in source
Mice bearing C26 colorectal tumours
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
Dose not stated
Source sentences
Summary
Biodistribution data showed a rapid blood clearance
1 context sentence(design, population, supporting numbers)
Summary · context
Biodistribution study was carried out in mice bearing C26 colorectal tumours.
Report a problemFND-1746054205
02AnimalAnimal study (in vivo)Activity measurement
In mice bearing C26 colorectal tumours, biodistribution data showed specific binding of the 18F-labelled VIP analogue towards receptor-positive tumours.
In plain wordsIn mice with colorectal tumours, the labelled VIP analogue bound specifically to tumours that carry the VIP receptor.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableBinding to receptor-positive tumours
Study
mousen: not reported in source
Mice bearing C26 colorectal tumours
Outcome group
Receptor activity and mechanism · Cancer
Studied dose
Dose not stated
Source sentences
Summary
specific binding towards receptor-positive tumours.
1 context sentence(design, population, supporting numbers)
Summary · context
Biodistribution study was carried out in mice bearing C26 colorectal tumours.
Report a problemFND-1746054206

Studies that did not test the peptide alone4

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

03LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneIn vitro (cell-free)Other
The 18F-labelled VIP analogue showed high stability in human serum albumin solution in vitro.
In plain wordsIn lab tests, the labelled VIP analogue stayed stable in a human albumin solution.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableIn vitro stability in human serum albumin solution
Study
n: not reported in source
Human serum albumin solution
Outcome group
Synthesis and manufacturing · Pharmacology
Source sentences
Summary
Results of in-vitro studies demonstrated a high stability in human serum albumin (HSA) solution.
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1746054204
04LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther
The 18F-labelled VIP analogue was made in more than 99% radiochemical purity within 60 minutes.
In plain wordsIn lab work, the labelled VIP analogue was made at more than 99% purity within 60 minutes.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRadiochemical purity of the labelled VIP analogue
Study
n: not reported in source
Outcome group
Synthesis and manufacturing · Pharmacology
Measurements
Radiochemical purity
> 99%
within 60 min
Source sentences
Summary
18F-(R8,15,21, L17)-VIP was obtained in greater than 99% radiochemical purity within 60 min
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1746054201
05LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther
The decay-corrected radiochemical yield of the 18F-labelled VIP analogue was 21.8 +/- 4.7% (n=5).
In plain wordsIn lab work, the labelled VIP analogue was made with a decay-corrected yield of 21.8%.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableRadiochemical yield of the labelled VIP analogue
Study
n: not reported in source
Outcome group
Synthesis and manufacturing · Pharmacology
Measurements
Radiochemical yield
21.8%
decay-corrected, n=5
Source sentences
Summary
in decay-for-corrected radiochemical yields of 21.8+/-4.7% (n=5)
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1746054202
06LabNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneOther designOther
The specific activity of the 18F-labelled VIP analogue was 17.76 GBq per micromole at the end of synthesis.
In plain wordsIn lab work, the labelled VIP analogue had a specific activity of 17.76 GBq per micromole at the end of synthesis.
Peptide
Vasoactive intestinal peptide (VIP, aviptadil)
Outcome
Not applicableSpecific activity of the labelled VIP analogue
Study
n: not reported in source
Outcome group
Synthesis and manufacturing · Pharmacology
Measurements
Specific activity
17.76 GBq/µmol
end of synthesis
Source sentences
Summary
a specific activity of 17.76 GBq x mumol(-1) at the end of synthesis (EOS).
In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).
Report a problemFND-1746054203

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
9 Oct 2026, 19:08 UTC
Study results updated
Version 1
9 Oct 2026, 12:41 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.